CommercialPrior AuthHigh impact
Abatacept (Orencia) (CPB 0720, reviewed 2026-07-01)
Aetna·Rheumatology, Dermatology, Oncology +1 more·Medical Policy
Effective date
Jul 1, 2026
We identified it
Aug 12, 2026
Summary
Aetna has implemented a restrictive prior authorization policy for Orencia IV (intravenous abatacept) effective immediately, requiring members new to targeted immune modulators to fail or be contraindicated to multiple lower-cost alternative biologics before Orencia IV is approved. This applies to rheumatoid arthritis, psoriatic arthritis, and other indications, with specific step-therapy sequences mandated for each condition.
Action Required
Effective immediately: (1) Billing team must implement mandatory precertification workflow for all Orencia IV (intravenous abatacept) requests via phone (866) 752-7021 or fax (888) 267-3277 before claims submission. (2) Providers (rheumatologists, dermatologists, oncologists, hematologists per specialty) must document and submit evidence of contraindication, intolerance, or inadequate response to ALL required step-therapy medications before Orencia IV authorization. For RA: Avtozma, Simponi Aria, and either Avsola/Inflectra/Renflexis (one-month trial each minimum). For PsA: Simponi Aria, Skyrizi, Pyzchiva (Sandoz-labeled preferred), Stelara, Tremfya, and either Avsola/Inflectra/Renflexis (one-month trial each minimum). (3) Update billing software and EMR templates to flag Orencia IV claims and require attachment of step-therapy documentation and precertification approval number before submission. (4) Front desk staff should inform patients that Orencia IV coverage requires sequential trial failures of other medications and precertification may take additional time. Failure to obtain precertification or provide step-therapy documentation will result in claim denials and patient liability. Contact Specialty Pharmacy Precertification for Statement of Medical Necessity forms.